Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

Core Insights - Ocular Therapeutix, Inc. plans to host a conference call and webcast on November 4, 2025, to discuss recent business progress and financial results for Q3 2025 [1][2] Company Overview - Ocular Therapeutix is an integrated biopharmaceutical company focused on redefining the retina experience [3] - The company’s investigational product AXPAXLI™ (OTX-TKI) is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and plans to initiate a Phase 3 program for non-proliferative diabetic retinopathy (NPDR) imminently [3] - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain, and OTX-TIC, an investigational product in Phase 2 for open-angle glaucoma or ocular hypertension [4]